Bortezomib in recurrent and/or refractory multiple myeloma

2005222 citationsJournal Article

Authors

Sundar Jagannath · Saint Vincent Health System

Bart Barlogie · University of Arkansas Medical Center

James R. Berenson · Institute for Myeloma & Bone Cancer Research

Seema Singhal · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Raymond Alexanian · The University of Texas MD Anderson Cancer Center

Gordan Srkalović · Cleveland Clinic

Robert Z. Orlowski

Abstract

Clinical experience in a limited number of patients with impaired renal function suggests that bortezomib provides clinical benefit with manageable toxicities in this high-risk population.

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 103, Issue 6, pp. 1195-1200

DOI: 10.1002/cncr.20888

Field-Weighted Citation Impact: 12.44